• 14
Reading Time: 5 minutes

Many diabetic foot ulcers are large, slow to close, or left behind after surgery to drain an infection or remove dead tissue. Once the wound bed is clean, well perfused and free of infection, waiting for it to close by itself can take months. A split-thickness skin graft (STSG) is one way to close these wounds faster. It uses a thin layer of the patient’s own skin, usually from the thigh, placed over the prepared wound. This post reviews what studies from the past decade show about how well STSGs work in the diabetic foot, which patients do best, and where the evidence is still limited.

How Well Do Skin Grafts Heal Diabetic Foot Wounds?

The broadest summary of controlled trials is a Cochrane review by Santema, Poyck and Ubbink (2016). It pooled 17 randomized trials with 1,655 participants. The review covered skin grafts and tissue replacement products together, and most of the trials tested bioengineered or donor-derived products rather than the patient’s own skin. Compared with standard care alone, grafting and tissue replacement increased the chance of complete healing (risk ratio 1.55; 95% CI 1.30–1.85). Only two trials reported amputation, and they showed fewer amputations with grafting (risk ratio 0.43). The authors rated this evidence as low to very low quality. They also noted that long-term outcomes and cost-effectiveness remain uncertain.

For autologous STSGs specifically, Yammine and Assi (2019) carried out a meta-analysis of 11 studies covering 757 patients and 759 diabetic foot and leg ulcers. The pooled healing rate was 85.5%, and the mean time to healing was about 5.4 weeks. Complication rates were low: 4.4% for graft-site infection, 1.7% for donor-site infection and 4.2% for ulcer recurrence. About 12% of patients needed a second graft. Most included studies were observational, so these figures reflect carefully selected patients.

Blood Flow: The Most Important Factor in Graft Success

A new graft has no blood supply of its own; it survives on fluid from the wound bed until new vessels grow into it, so success depends heavily on blood flow. Tefera and colleagues (2019) reviewed 47 foot and ankle wounds in 35 patients with peripheral arterial disease (PAD), almost all of whom had diabetes. Each patient had an angiogram and, where possible, revascularization before grafting. Overall, 76.6% of the wounds eventually healed, with a median time of 54 days. Arterial anatomy made a large difference. When the pedal arch (the arterial loop across the foot) was fully open, 62.5% of wounds had healed at one month, compared with 17.1% when it was blocked or incomplete. Six extremities (15.8%) later needed a major amputation, and congestive heart failure was much more common among the patients who lost a limb.

Does Blood Sugar Control Predict Graft Failure?

Sanniec and colleagues (2017, Journal of the American Podiatric Medical Association) reviewed 43 STSGs to the foot and ankle in patients with diabetes. Of these, 27 healed with more than 90% graft take, and 16 grafts failed. The average HbA1c was similar in the two groups (8.7% in grafts that healed and 8.4% in grafts that failed; P = .72), and wound size did not predict failure either. The mean time to healing was about 6.5 weeks. The authors concluded that, on preliminary data, an elevated HbA1c by itself should not rule out grafting.

Supporting the Graft: Offloading and Negative Pressure

Grafts most often fail because of shear, fluid collecting under the graft, or infection. Many surgeons now hold the graft in place with negative pressure wound therapy (NPWT) for the first several days. In a small case series, Gkotsoulias (2020, Foot & Ankle Specialist) reported 100% graft take at 14 days in 11 diabetic foot and ankle wounds supported with NPWT. Mean healing time was about 17 days, with no infections. Because the study had no comparison group, it cannot show that NPWT itself caused the good results. In the Sanniec series, the NPWT dressing neither improved nor harmed graft take. Either way, the grafted foot needs protection from weight-bearing and shear.

Limitations of the Evidence

Most published data on autologous STSGs in diabetes come from retrospective, single-centre series with small numbers of patients. The randomized trials in the Cochrane review mostly tested manufactured skin substitutes rather than the patient’s own skin. Definitions of graft take and follow-up periods vary, and few studies measured recurrence or amputation reliably. A healed graft does not fix the underlying problems of neuropathy, deformity and high plantar pressure. Lifelong prevention measures remain necessary after the wound closes.

Conclusion

In carefully selected patients, a split-thickness skin graft can close a diabetic foot wound in weeks rather than months, with high reported healing rates and few complications. The best results come when infection is controlled, the wound bed has been debrided and blood flow is adequate. In patients with PAD, the state of the foot’s arteries, especially the pedal arch, strongly influences whether the graft takes. HbA1c alone does not appear to predict graft failure. Bolstering the graft and offloading the foot during the early healing period are key parts of care.

References

  • Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews. 2016;(2):CD011255.
  • Yammine K, Assi C. A meta-analysis of the outcomes of split-thickness skin graft on diabetic leg and foot ulcers. International Journal of Lower Extremity Wounds. 2019.
  • Tefera EA, Akbari CM, Kennedy-Evans KL, et al. Outcomes of split-thickness skin grafting for foot and ankle wounds in patients with peripheral arterial disease. Wounds. 2019;31(11):272–278.
  • Sanniec K, Nguyen T, van Asten S, La Fontaine J, Lavery LA. Split-thickness skin grafts to the foot and ankle of diabetic patients. Journal of the American Podiatric Medical Association. 2017;107(5):365–368.
  • Gkotsoulias E. Split thickness skin graft of the foot and ankle bolstered with negative pressure wound therapy in a diabetic population: the results of a retrospective review and review of the literature. Foot & Ankle Specialist. 2020;13(5):383–391.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.